The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort-Reference-Cited by-同舟云学术

The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort

Published:2018-01 Issue:1 Volume:4 Page:150-160
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Tariot Pierre N.¹,Lopera Francisco²,Langbaum Jessica B.¹,Thomas Ronald G.³,Hendrix Suzanne⁴,Schneider Lon S.⁵,Rios‐Romenets Silvia²,Giraldo Margarita²,Acosta Natalia²,Tobon Carlos²,Ramos Claudia²,Espinosa Alejandro²,Cho William⁶,Ward Michael⁶,Clayton David⁶,Friesenhahn Michael⁶,Mackey Howard⁶,Honigberg Lee⁶,Sanabria Bohorquez Sandra⁶,Chen Kewei¹,Walsh Trisha¹,Langlois Carolyn¹,Reiman Eric M.¹,

Affiliation:

1. Banner Alzheimer's InstitutePhoenixAZUSA

2. Grupo de NeurocienciasUniversidad de Antioquia, SIUMedellínColombia

3. Department of NeurosciencesUniversity of California San Diego School of MedicineLa JollaCAUSA

4. Pentara CorporationSalt Lake CityUTUSA

5. USC State of California Alzheimer's Disease Research and Clinical Center, Keck Medicine of USCLos AngelesCAUSA

6. Genentech, a Member of the Roche GroupSouth San FranciscoCAUSA

Funder

National Institute on Aging

NOMIS Stiftung

Flinn Foundation

AstraZeneca